Slimming Treatment Device

K161892 · Beijing Honkon Technologies Co., Ltd. · NUV · Mar 2, 2017 · General, Plastic Surgery

Device Facts

Record IDK161892
Device NameSlimming Treatment Device
ApplicantBeijing Honkon Technologies Co., Ltd.
Product CodeNUV · General, Plastic Surgery
Decision DateMar 2, 2017
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4810
Device ClassClass 2
AttributesTherapeutic

Intended Use

The HONKON-Slimming I+/HONKON-Slimming III+ are indicated for the relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, temporary reduction in the appearance of cellulite, and for temporary reduction of thighs circumferences.

Device Story

Non-invasive body shaping device; combines infrared (IR) light (700-2000nm), bi-polar radio-frequency (RF) energy (1MHz), pulsed vacuum, and mechanical massage rollers. IR light penetrates skin to expand blood vessels and improve circulation. RF energy heats subcutaneous tissue to enhance enzyme activity, releasing triglycerides from fat cells. Pulsed vacuum and rollers provide mechanical tissue manipulation, lymphatic drainage, and skin relaxation. Vacuum pressure (up to 8kg) draws tissue between bipolar RF tips to ensure energy delivery to fat layers. Used in clinical settings by trained operators. Output includes thermal and mechanical effects on skin/subcutaneous tissue. Benefits include temporary cellulite reduction, thigh circumference reduction, and relief of muscle aches/spasms.

Clinical Evidence

No clinical data provided. Bench testing only, including electrical safety (IEC 60601-1), electromagnetic compatibility (IEC 60601-1-2), and high-frequency surgical equipment safety (IEC 60601-2-2). Biocompatibility testing (cytotoxicity, irritation, sensitization) performed per ISO 10993 standards.

Technological Characteristics

Materials: Handpiece and suction roller components. Energy: 1MHz Bi-Polar RF (40-400W), 700-2000nm Infrared light. Mechanical: Pulsed vacuum (-0.08 to -0.01 MPa) and massage rollers. Connectivity: Standalone. Safety Standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-2-2. Biocompatibility: ISO 10993-5 (cytotoxicity), ISO 10993-10 (irritation/sensitization).

Indications for Use

Indicated for relief of minor muscle aches/pain, muscle spasms, temporary improvement of local blood circulation, temporary reduction in cellulite appearance, and temporary reduction of thigh circumference.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines connecting them. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 March 2, 2017 Beijing Honkon Technologies Co., Ltd % Ray Wang General Manager Beijing Believe Technology Service Co., Ltd. 5-1206, Build 332, DaFangJu, No.25 BanBiDian Rd. LiYuan Town, TongZhou District Beijing, 101121 CN Re: K161892 Trade/Device Name: Slimming Treatment Device Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument for Use in General and Plastic Surgery and in Dermatology Regulatory Class: Class II Product Code: NUV, ISA Dated: January 18, 2017 Received: January 23, 2017 Dear Mr. Wang: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply {1}------------------------------------------------ with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801; medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely, # Jennifer R. Stevenson For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration # Indications for Use 510(k) Number (if known) K161892 Device Name Slimming Treatment Device Indications for Use (Describe) The HONKON-Slimming I+/HONKON-Slimming III+ are indicated for the relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, temporary reduction in the appearance of cellulite, and for temporary reduction of thighs circumferences. | Type of Use (Select one or both, as applicable) | | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | <span style="display:inline-block; margin-right: 5px;"> <div style="display:inline-block; vertical-align:middle; width:15px; height:15px; border: 1px solid black;"> <div style="text-align:center;">✓</div> </div> </span> Prescription Use (Part 21 CFR 801 Subpart D) | <span style="display:inline-block; margin-right: 5px;"> <div style="display:inline-block; vertical-align:middle; width:15px; height:15px; border: 1px solid black;"></div> </span> Over-The-Counter Use (21 CFR 801 Subpart C) | CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ***DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*** The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below. {3}------------------------------------------------ # 510(k) Summary This 510(k) Summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of SMDA 1990 and Title 21, CFR Section 807.92. The assigned 510(k) Number: K161892 - 1. Date of Preparation: 03/01/2017 - 2. Sponsor Identification ## BEIJING HONKON TECHNOLOGIES CO., LTD 72 building, 16#Huanke middle road, Golden bridge scientific and technological industry base Tongzhou Yard, Zhongguan village technological Yard, Tongzhou district, Beijing, China. Establishment Registration Number: 3009488834 Contact Person: Li Yanzhe Position: Registration Manager Tel: +86 10 56370050 ext. 607 Fax: +86 10 56370076 Email:small@honkonlaser.com - 3. Designated Submission Correspondent Mr. Ray Wang ## Beijing Believe Technology Service Co., Ltd. 5-1206, Build 332, DaFangJu, No.25 BanBiDian Rd., LiYuan Town, TongZhou District, Beijing, 101121, China Tel: +86-18910677558 Fax: +86-10-52214696 Email: ray.wang@believe-med.com {4}------------------------------------------------ #### 4. Identification of Proposed Device Trade Name: Slimming Treatment Device Common Name: Massager, Vacuum, Light Induced Heating. Model(s): HONKON-Slimming I+、HONKON-Slimming III+ Regulatory Information: Classification Name: Laser surgical instrument for use in general and plastic surgery and in dermatology; Classification: II; Product Code: NUV、ISA: Regulation Number: 21 CFR 878.4810; Review Panel: General & Plastic Surgery; ### Intended Use Statement: The HONKON-Slimming I-/HONKON-Slimming III+ are indicated for the relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation,temporary reduction in the appearance of cellulite, and for temporary reduction of thighs circumferences. #### Device Description: The HONKON-Slimming I+ and HONKON-Slimming III+ are the non-invasive body shaping product to combine four different technologies including IR (infrared), Bi-Polar RF (radio-frequency) and mechanical tissue manipulation using pulsed vacuum and massage rollers. The combination of the IR and vacuum coupled RF technologies causes deep heating of the connective tissue including the fibrous septae which in turn promotes an increase in local cellular reduction. The additional mechanical tissue manipulation of the device causes an immediate increase in circulation and lymphatic drainage, both essential components for healthy skin structure. The HONKON-Slimming I+ and HONKON-Slimming III+ can output infrared light with wavelength 700-2000nm, the infrared light can penetrate whole skin tissue. The infrared light has the effect to expand blood vessels, temporary improvement of local blood circulation; At the same time, this spectrum has a good efficacy for temporary reduction in the appearance of cellulite, and for temporary reduction of thighs circumferences.. The HONKON-Slimming I+ and HONKON-Slimming III+ can output 1MHz frequency, produce RF energy from X, Y and Z directions in the subcutaneous tissue. Temperature of skin tissues becomes higher, Enzyme activity was enhanced so that fat cells can be fully released within the triglyceride; Triglycerides in the fat under the action of enzymes, cracking into fatty acids and {5}------------------------------------------------ glycerol. Massage rollers has obvious mechanical compression to skin tissues. Meanwhile, deep negative pressure gives skin and muscles full relaxation and rest. Maximum 8kg negative pressure can absorb all skin tissues into the gap between the bipolar RF tips, ensure RF energy can reach fat layers. Based on this,the HONKON-Slimming I+/HONKON-Slimming III+ are indicated for the relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, temporary reduction in the appearance of cellulite, and for temporary reduction of thighs circumferences.. - న. Identification of Predicate Device(s) Predicate Device I : 510(k) Number: K090221 Predicate Device Name: Reaction™ System Manufacturer: Viora Ltd. Predicate Device II : 510(k) Number: K122579 Predicate Device Name: VelaShape Manufacturer: Syneron Medical Ltd. #### Non-Clinical Test Conclusion 6. Non clinical tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards: a)IEC 60601-1-2:2007, Medical Electrical Equipment - Part 1-2: General Requirements for Safety - Collateral Standard: Electromagnetic Compatibility -- Requirements and Tests. b)IEC 60601-1:2005/A1:2012. Medical electrical equipment - Part 1: General reguirements for basic safety and essential performance c)IEC60601-2-2:2009+C1:2014,Medical Electrical Equipment - Part 2-2: Particular Requirements for The Basic Safety And Essential Performance Of High Frequency Surgical Equipment And High Frequency Surgical Accessories [Including: Technical Corrigendum 1 (2014)] - 7. Clinical Test Conclusion No clinical study is included in this submission. {6}------------------------------------------------ #### Substantially Equivalent (SE) Comparison 8. | ITEM | Proposed Device<br>HONKON-Slimming I+<br>HONKON-SlimmingIII+ | Predicate Device<br>ReactionTM system<br>(K090221) | Predicate Device<br>VelaShape<br>(K122579) | Remark | |-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------| | | Product<br>Code | NUV、ISA | NUV、ISA | NUV | | Regulation<br>No. | 21 CFR 878.4810 | 21 CFR 878.4810 | 21 CFR 878.4810 | SE | | Class | II | II | II | SE | | Intended<br>Use | The HONKON-Slimming<br>I+/HONKON-Slimming<br>III+ are indicated for the<br>relief of minor muscle<br>aches and pain, relief of<br>muscle spasm, temporary<br>improvement of local<br>blood circulation,<br>temporary reduction in<br>the appearance of<br>cellulite, and for<br>temporary reduction of<br>thighs circumferences. | The ReactionTM system is<br>intended for the treatment<br>of the following medical<br>conditions, using the<br>B-contour and F-contour<br>applicators for<br>delivering non thermal RF<br>combined with massage:<br>- relief of minor muscle<br>aches and pain, relief of<br>muscle spasm,<br>temporary improvement.<br>Of local blood<br>circulation,and<br>- temporary reduction in<br>the appearance of cellulite.<br>Using the ST applicator for<br>delivering RF, the<br>ReactionTM system is<br>intended for the treatment<br>of relief of minor muscle<br>aches and pain.relief<br>of.muscle spasm,<br>temporary improvement of<br>local blood circulation. | The VelaShape is<br>indicated for the<br>relief of minor<br>muscle aches and<br>pain, relief of<br>muscle spasm,<br>temporary<br>improvement of<br>local blood<br>circulation,<br>temporary reduction<br>in the appearance of<br>cellulite, and for<br>temporary reduction<br>of thighs<br>circumferences. | SE | | ITEM | Proposed Device<br>HONKON-SlimmingI+<br>HONKON-SlimmingIII+ | Predicate Device<br>Reaction™ system<br>(K090221) | Predicate Device<br>VelaShape<br>(K122579) | Remark | | RF Output<br>Energy | 40-400W | Up to 50w | Up to 150W | Discussion<br>(a) | | RF Output<br>Frequency | 1MHz | 0.8 MHz, 1.7 MHz,<br>2.45 MHz | N.A | SE | | Max.<br>RF output<br>energy density | XF-I+:12.14W/cm2<br>XF-VII+:27W/cm2 | 78.125W/cm2<br>4.76W/cm2<br>33.33W/cm2 | 115.38W/cm2<br>6.67W/cm2<br>12 W/cm2<br>9.38W/cm2 | SE | | Infrared energy | XF-I+ & XF-VII+:<br>I: 5W II: 7W III: 8W<br>IV : 9W V :10W | N.A | Up to 3.3W | Discussion<br>(b) | | Infrared<br>wavelengths | 700-2000nm | N.A. | 850nm | SE | | Max. IR output<br>energy density | XF-I+:0.30W/cm2<br>XF-VII+:0.67W/cm2 | / | 2.54W/cm2<br>0.44W/cm2<br>0.26W/cm2<br>0.21W/cm2 | SE | | Vacuum | Pulsed<br>(-0.08Mpa -- -0.01Mpa) | Pulsed | Pulsed | SE | | Mechanical<br>Massage | Yes | Yes | N.A. | SE | | Treatment Area | XF-I+: 3294 mm²<br>XF-VII+: 1482mm² | 64 mm²<br>1050 mm²<br>150 mm² | VContour<br>Applicator:<br>Small Cover<br>Medium Cover<br>Large Cover:<br>130 mm²<br>750 mm²<br>1250 mm²<br>VSmooth<br>Applicator:<br>1600 mm² | Discussion<br>(c) | | Weight | 48KG | 17kg. - desktop<br>19 kg. - wheel base | 20kg / 44lbs | Discussion<br>(d) | | Size(mm)<br>L*W*H | 434mm * 531mm *1354mm<br>(Slimming I+)<br>531mm * 441mm *1716mm<br>(Slimming III+) | 400*350* 450 | 380* 490 *1320 | Discussion<br>(e) | | ITEM | Proposed Device<br>HONKON-Slimming I+<br>HONKON-SlimmingIII+ | Predicate Device<br>ReactionTM system<br>(K090221) | Predicate Device<br>VelaShape (K122579) | Remark | | Power<br>supply | 110V, 60HZ | 90-264 VAC; 50/60 Hz;<br>Single Phase | 110VA;<br>50Hz; single phase | SE | | Electrical<br>Safety | The proposed devices were<br>tested to demonstrated to<br>comply with IEC 60601-1 | The proposed devices<br>were tested to<br>demonstrated to comply<br>with IEC 60601-1 | The proposed devices<br>were tested to<br>demonstrated to<br>comply with IEC<br>60601-1 | SE | | EMC | The proposed devices were<br>tested to demonstrated to<br>comply with IEC 60601-1-2 | The proposed devices<br>were tested to<br>demonstrated to comply<br>with IEC 60601-1-2 | The proposed devices<br>were tested to<br>demonstrated to<br>comply with IEC<br>60601-1-2 | SE | | Patient<br>Contact<br>Material | Handpiece<br>Suction roller | Handpiece<br>Suction roller | Handpiece<br>Suction roller | SE | | Biocompatibility | | | | | | Cytotoxicity | No toxicity<br>(ISO 10993-5) | No toxicity (ISO 10993-5) | No toxicity (ISO<br>10993-5) | SE | | Irritation | Applied sample did not<br>induce irritation to skin.<br>(ISO 10993-10) | Applied sample did not<br>induce irritation to skin.<br>(ISO 10993-10) | Applied sample did<br>not induce irritation to<br>skin. (ISO 10993-10) | SE | | Sensitization | The test article showed<br>no signification evidence<br>of causing skin<br>sensitization in the<br>guinea pig .(ISO<br>10993-10) | The test article showed no<br>signification evidence of<br>causing skin sensitization<br>in the guinea pig .(ISO<br>10993-10) | The test article<br>showed no<br>signification evidence<br>of causing skin<br>sensitization in the<br>guinea pig .(ISO<br>10993-10) | SE | # Table 1 General Comparison Table 2 Performance Comparison {7}------------------------------------------------ {8}------------------------------------------------ Table 3 Safety Comparison ## Discussion: The proposed device has the following differences with the predicate device: - a. RF Output Energy, base on the nonclinical tests (IEC 60601-2-2) performed, the proposed device is as safe, as effective, and performs as well as the predicated device. - b. Infrared energy, base on the nonclinical tests (IEC 60601-1) performed for the risk of heat, the proposed device is as safe, as effective, and performs as well as the predicated device. {9}------------------------------------------------ - Treatment Area, which only affect the treatment area's size, no concerned with safety and effective, c. the proposed device is as safe, as effective, and performs as well as the predicated device. - Weight, base on the nonclinical tests (IEC 60601-1) performed for the risk of mechanical, the d. proposed device is as safe, as effective, and performs as well as the predicated device. - Size, base on the nonclinical tests (IEC 60601-1) performed for the risk of mechanical, the proposed e. device is as safe, as effective, and performs as well as the predicated device. #### 9. Substantially Equivalent (SE) Conclusion Based on the comparison and analysis above, the proposed devices are determined to be Substantially Equivalent (SE) to the predicate devices.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%